Nimitt helps providers across the nation optimize operational, financial, and revenue cycle processes and understand the associated reimbursement implications of both government and commercial payment methods. Our deep understanding of provider operations – combined with our advocacy and payment policy successes – uniquely positions us to address a large range of topics.

  • Provider Review focused on SCT, CAR-T and other novel cell and gene therapies that includes: 
    • Stem cell transplant / bone marrow transplant (SCT / BMT)
    • Chimeric Antigen Receptor T-Cell (CAR-T) therapies and 
    • Other novel cell and gene therapies
  • Claims data analysis
  • Education and training on topics including:
    • Coding and billing requirements per the authoritative sources 
    • Decoding payer coverage policies for SCT and CAR-T
    • Clinical trials billing
    • Drug administration (injections/infusions) coding and billing
    • Implementing Medicare transmittal and claims processing manual instructions
    • Implementing annual CMS payment system (IPPS, OPPS, MPFS) rule changes
    • Implications of patient status and observation care on reimbursement
    • Managing and appealing claim denials
    • Reimbursement support, including how to set defensible charges 
  • Managed care guidance and support for contracting
    • Contract language assessment 
    • Insights into best practices
    • Review of global packets for payment accuracy 
    • Strategic support to negotiate optimal managed care agreements
  • Medical record reviews
    • Cell and gene therapies
    • Drug administration/injections and infusions
    • E/M visits on same day as chemotherapy
    • Drugs and biologicals billing, including waste billing
    • Others upon request
  • Nimitt Perspectives: provider resources on key health policies
  • On-call technical assistance to address operational and financial questions
  • Provider Roundtable (PRT) advocacy initiative